Podcast Episode
The trial represents a significant step toward making Alzheimer's diagnosis accessible to the millions of people who currently cannot access gold standard testing methods. The study is expected to complete in 2028.
The finger-prick test uses a plasma separation card that does not require refrigeration and can be stored and shipped to laboratories at ambient temperature. This breakthrough opens the possibility of at-home testing, with samples simply mailed for analysis, dramatically expanding access to diagnostic testing.
Doctor Giovanna Lalli, director of strategy and operations at LifeArc, emphasized the importance of developing cheaper, scalable and more accessible tests in the battle against this devastating condition. The prospect of a finger-prick blood test for Alzheimer's disease will allow more patients to access new drugs currently being developed to slow disease progression in its early stages.
Two other markers, glial fibrillary acidic protein and neurofilament light polypeptide, were also successfully measured and showed strong agreement with traditional tests. Participants successfully collected their own finger-prick samples without the guidance of study personnel after watching trained staff and receiving written instructions.
Black and Hispanic individuals are twice as likely to develop Alzheimer's compared to white populations, yet they remain dramatically underrepresented in clinical trials, with participation rates often below 20 percent. The accessibility of finger-prick testing could help address these disparities by removing barriers to participation.
Doctor Michael Sandberg, a London general practitioner who participated in the trial after watching his mother's decline from Alzheimer's, received a negative result. He noted that being able to screen people to see if they are on the way to developing dementia without hugely expensive scans and lumbar punctures will be fundamental to fulfilling the potential of new treatments.
An estimated 982,000 people live with dementia in the UK, with more than a third lacking a diagnosis. The combination of accessible testing and effective early intervention treatments could dramatically change outcomes for millions of people worldwide.
The research represents the first large-scale validation of this accessible testing approach and could fundamentally transform how Alzheimer's disease is detected, diagnosed, and treated in the coming years.
Finger-Prick Blood Test Could Transform Early Alzheimer's Detection
January 19, 2026
Audio archived. Episodes older than 60 days are removed to save server storage. Story details remain below.
Scientists are testing whether a simple finger-prick blood test could revolutionize Alzheimer's diagnosis by detecting the disease years before symptoms emerge, potentially replacing the costly and invasive procedures that currently leave the vast majority of patients without access to proper testing.
Major International Trial Underway
The Bio-Hermes-002 trial, led by medical research organization LifeArc and the Global Alzheimer's Platform Foundation with support from the UK Dementia Research Institute, has enrolled 883 of its target 1,000 participants across 25 sites in the UK, United States, and Canada. More than 360 volunteers have already completed the test, which measures three proteins in the blood that are linked to Alzheimer's disease: phosphorylated tau 217, glial fibrillary acidic protein, and neurofilament light polypeptide.The trial represents a significant step toward making Alzheimer's diagnosis accessible to the millions of people who currently cannot access gold standard testing methods. The study is expected to complete in 2028.
Addressing Critical Accessibility Barriers
Current Alzheimer's diagnosis requires specialized brain scans or lumbar punctures to extract cerebrospinal fluid. These procedures are expensive, invasive, and inaccessible for most patients. According to recent reports, only about 2 in every 100 Alzheimer's patients are offered these gold standard tests.The finger-prick test uses a plasma separation card that does not require refrigeration and can be stored and shipped to laboratories at ambient temperature. This breakthrough opens the possibility of at-home testing, with samples simply mailed for analysis, dramatically expanding access to diagnostic testing.
Doctor Giovanna Lalli, director of strategy and operations at LifeArc, emphasized the importance of developing cheaper, scalable and more accessible tests in the battle against this devastating condition. The prospect of a finger-prick blood test for Alzheimer's disease will allow more patients to access new drugs currently being developed to slow disease progression in its early stages.
Strong Scientific Validation
The trial comes as separate research published January 5 in Nature Medicine demonstrated that finger-prick blood samples can accurately measure Alzheimer's biomarkers. The DROP-AD study, involving 337 participants across 7 European centers, found that p-tau217 levels in finger-prick samples matched standard blood tests and predicted Alzheimer's-related changes in spinal fluid with 86 percent accuracy.Two other markers, glial fibrillary acidic protein and neurofilament light polypeptide, were also successfully measured and showed strong agreement with traditional tests. Participants successfully collected their own finger-prick samples without the guidance of study personnel after watching trained staff and receiving written instructions.
Focus on Diversity and Representation
Professor Henrik Zetterberg, who leads the Biomarker Factory at the UK Dementia Research Institute, emphasized the Bio-Hermes-002 trial's diversity goals. The study aims to recruit 30 percent of volunteers from under-represented groups, addressing a critical gap in Alzheimer's research.Black and Hispanic individuals are twice as likely to develop Alzheimer's compared to white populations, yet they remain dramatically underrepresented in clinical trials, with participation rates often below 20 percent. The accessibility of finger-prick testing could help address these disparities by removing barriers to participation.
Timing Critical as New Treatments Emerge
Early diagnosis has become increasingly urgent as disease-modifying treatments enter clinical practice. FDA-approved drugs lecanemab and donanemab have demonstrated efficacy in slowing cognitive decline, but they work best when administered early in the disease process.Doctor Michael Sandberg, a London general practitioner who participated in the trial after watching his mother's decline from Alzheimer's, received a negative result. He noted that being able to screen people to see if they are on the way to developing dementia without hugely expensive scans and lumbar punctures will be fundamental to fulfilling the potential of new treatments.
An estimated 982,000 people live with dementia in the UK, with more than a third lacking a diagnosis. The combination of accessible testing and effective early intervention treatments could dramatically change outcomes for millions of people worldwide.
Implications for Research and Clinical Practice
While dried blood testing is not yet suitable for patient management, it may serve as an initial screening or triage tool to identify individuals who would benefit from confirmatory PET imaging or cerebrospinal fluid testing. The technology could enable remote participation in research studies, opening up Alzheimer's research to people in rural areas, those with mobility issues, and anyone who cannot regularly travel to specialized medical centers.The research represents the first large-scale validation of this accessible testing approach and could fundamentally transform how Alzheimer's disease is detected, diagnosed, and treated in the coming years.
Published January 19, 2026 at 3:52pm
